Community benefits of mass distribution of three types of dual-active-ingredient long-lasting insecticidal nets against malaria prevalence in Tanzania: evidence from a 3-year cluster-randomized controlled trial

Author:

Lukole Eliud AndreaORCID,Cook Jackie,Mosha Jacklin F,Matowo Nancy SORCID,Kulkarni Manisha AORCID,Mallya Elizabeth,Aziz Tatu,Martin JacklinORCID,Rowland Mark,Kleinschmidt Immo,Manjurano AlphaxardORCID,Kinung’hi Safari,Mosha Franklin W,Protopopoff Natacha

Abstract

AbstractBackgroundLong-lasting insecticidal nets (LLINs) were once fully effective for the prevention of malaria; however, mosquitoes have developed resistance to pyrethroids, the main class of insecticides used on nets. Dual active ingredient LLINs (dual-AI LLINs) have been rolled out as an alternative to pyrethroid (PY)-only LLINs to counteract this. Understanding the minimum community usage at which these novel nets generate an effect that also benefits non-net users against malaria infection is vital for planning net distribution strategies and mobilization campaigns.MethodsWe conducted a secondary analysis of a 3-year randomized controlled trial (RCT) in 84 clusters in North-western Tanzania to evaluate the effectiveness of three dual-AI LLINs: pyriproxyfen and alpha(α)-cypermethrin (pyriproxyfen-PY), chlorfenapyr and α-cypermethrin (chlorfenapyr-PY), and the synergist piperonyl-butoxide and permethrin (PBO-PY) compared to α-cypermethrin only nets (PY-only). We measured malaria infection prevalence using 5 cross-sectional surveys between 2020 and 2022. We assessed net usage at the cluster level and malaria infection in up to two children aged between 6 months and 14 years in 45 households per cluster and compared infection prevalence between net users and non-users with the different net types and usage levels.FindingsA total of 22,479 children from 12,654 households were tested for malaria using rapid diagnostic tests in January 2020, 2021, & 2022 and July 2020 & 2021. In all surveys combined, 23% (5,062/22,479) of children reported not using a net the night before the surveys. The proportion of non-net users was highest in the later surveys. Across all study arms and at each time point, users of nets had significantly lower malaria infection than non-users. Overall, malaria prevalence was 52% (2649/5062) among non-net users and 32% (5572/11845) among users (of any net). Among non-net users, community-level usage of >40% of dual-AI LLIN was significantly associated with protection against malaria infection: chlorfenapyr-PY (OR: 0.44 (95% CI: 0.27-0.71), p=0.0009), PBO-PY (OR: 0.55 (95% CI: 0.33-0.94), p=0.0277) and pyriproxyfen-PY (OR: 0.61 (95% CI: 0.37-0.99), p=0.0470) compared with non-users in clusters with >40% usage of PY-only LLINs. There was weak evidence of protection against malaria infection to non-net users in the chlorfenapyr-PY arm when community-level usage was ≤40% (OR: 0.65 (95% CI: 0.42-1.01), p=0.0528) compared to those living in clusters with >40% usage of pyrethroid-only LLINs. The study was limited to non-users which were defined as participants who did not sleep under any net the night before. This might not capture occasional net usage during the week.ConclusionOur study demonstrated that at a community usage of 40% or more of dual-AI LLINs, non-net users benefited from the presence of these nets. Noticeably, even when usage was ≤40% in the chlorfenapyr-PY arm, non-users were better protected than non-users in the higher coverage PY-only arm. The greater difference in malaria risk observed between users and non-users across all study arms indicates that nets play a crucial role in providing personal protection against malaria infection for the people using the net and that net usage needs to be maximized to realize the full potential of all nets.FundingDepartment for International Development, UK Medical Research Council, Wellcome Trust, and Department of Health and Social Care (#MR/R006040/1). The Bill and Melinda Gates Foundation via the Innovative Vector Control Consortium (IVCC).

Publisher

Cold Spring Harbor Laboratory

Reference49 articles.

1. Malaria: Global progress 2000 – 2015 and future challenges;Infect Dis Poverty,2016

2. WHO, World malaria report 2022. 2022.

3. WHO, World malaria report 2019. 2019: Geneva.

4. WHO, World Malaria report 2023.

5. Plasmodium malariae : Parasite and Disease

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3